Renaissance Technologies’s Provention Bio PRVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-41,100
Closed -$991K – 4436
2023
Q1
$991K Buy
+41,100
New +$516K ﹤0.01% 2483
2022
Q4
– Sell
-31,321
Closed -$141K – 4527
2022
Q3
$141K Sell
31,321
-135,426
-81% -$617K ﹤0.01% 3495
2022
Q2
$667K Buy
+166,747
New +$790K ﹤0.01% 2976
2021
Q3
– Sell
-65,300
Closed -$550K – 3971
2021
Q2
$550K Sell
65,300
-164,100
-72% -$1.32M ﹤0.01% 2926
2021
Q1
$2.41M Buy
+229,400
New +$3.23M ﹤0.01% 2102
2020
Q2
– Sell
-74,796
Closed -$688K – 3864
2020
Q1
$688K Buy
+74,796
New +$964K ﹤0.01% 2603
2019
Q3
– Sell
-15,600
Closed -$189K – 3803
2019
Q2
$189K Buy
+15,600
New +$84.9K ﹤0.01% 3311

Other funds holding PRVB

Renaissance Technologies's PRVB Position: Q2 2023 in Review

Renaissance Technologies sold out of Provention Bio (PRVB) in Q2 2023, closing a stake of 41,100 shares — an estimated $991K sold.

Renaissance Technologies first reported a position in PRVB in Q2 2019 and held it in 7 quarters. The position peaked at $2.41M in Q1 2021. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Renaissance Technologies reported no remaining Provention Bio position as of Q2 2023 after selling out during the quarter.
  • Renaissance Technologies sold 41,100 Provention Bio shares in Q2 2023, an estimated $991K.
  • Renaissance Technologies first reported a position in Provention Bio in Q2 2019 and held it in 7 quarters.
  • Renaissance Technologies's Provention Bio position peaked at $2.41M in Q1 2021.
  • 1 fund tracked by Wall St. Rank held Provention Bio as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.